Artificial intelligence aids in development of nanomedicines for cancer management

Over the last decade, the nanomedicine has experienced unprecedented development in diagnosis and management of diseases. A number of nanomedicines have been approved in clinical use, which has demonstrated the potential value of clinical transition of nanotechnology-modified medicines from bench to bedside. The application of artificial intelligence (AI) in development of nanotechnology-based products could transform the healthcare sector by realizing acquisition and analysis of large datasets, and tailoring precision nanomedicines for cancer management. AI-enabled nanotechnology could improve the accuracy of molecular profiling and early diagnosis of patients, and optimize the design pipeline of nanomedicines by tuning the properties of nanomedicines, achieving effective drug synergy, and decreasing the nanotoxicity, thereby, enhancing the targetability, personalized dosing and treatment potency of nanomedicines. Herein, the advances in AI-enabled nanomedicines in cancer management are elaborated and their application in diagnosis, monitoring and therapy as well in precision medicine development is discussed.

Automated summary

In the past decade, nanomedicine has seen unprecedented development in disease diagnosis and treatment. Several nanomedicines have been approved for clinical use, demonstrating the potential value of transitioning nanotechnology-modified medicines from the lab to the bedside. The application of artificial intelligence (AI) in the development of nanotechnology-based products has the potential to transform healthcare by enabling the acquisition and analysis of large datasets and tailoring precision nanomedicines for cancer management.